Gulrayz Ahmed

475 total citations
27 papers, 179 citations indexed

About

Gulrayz Ahmed is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Pathology and Forensic Medicine. According to data from OpenAlex, Gulrayz Ahmed has authored 27 papers receiving a total of 179 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Public Health, Environmental and Occupational Health and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Gulrayz Ahmed's work include CAR-T cell therapy research (6 papers), CNS Lymphoma Diagnosis and Treatment (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Gulrayz Ahmed is often cited by papers focused on CAR-T cell therapy research (6 papers), CNS Lymphoma Diagnosis and Treatment (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Gulrayz Ahmed collaborates with scholars based in United States, Pakistan and Canada. Gulrayz Ahmed's co-authors include Mehdi Hamadani, Nirav N. Shah, Mustafa Abbas, Sherry‐Ann Brown, Lisa B. Weissmann, Nathan J. Smith, Michael T. Cain, Pippa Simpson, Kathryn T. Hall and Zahid Memon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and BMC Public Health.

In The Last Decade

Gulrayz Ahmed

24 papers receiving 177 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gulrayz Ahmed United States 7 58 50 50 28 27 27 179
Elliot Dickerson United States 10 28 0.5× 113 2.3× 23 0.5× 9 0.3× 35 1.3× 13 296
Alexander T. Ruutiainen United States 8 79 1.4× 56 1.1× 31 0.6× 6 0.2× 16 0.6× 14 314
Varidh Katiyar India 9 15 0.3× 109 2.2× 17 0.3× 53 1.9× 5 0.2× 37 216
Lydia Chelala United States 10 29 0.5× 38 0.8× 10 0.2× 11 0.4× 15 0.6× 35 264
Felicity Allen United Kingdom 9 15 0.3× 34 0.7× 15 0.3× 54 1.9× 5 0.2× 15 327
M. Perrin France 9 18 0.3× 66 1.3× 63 1.3× 11 0.4× 4 0.1× 39 238
Paola Solís-Pazmiño United States 10 31 0.5× 64 1.3× 16 0.3× 8 0.3× 7 0.3× 31 201
Matthew Gardiner United States 11 13 0.2× 73 1.5× 5 0.1× 16 0.6× 18 0.7× 26 322
Kourosh Karimi Yarandi Iran 7 17 0.3× 206 4.1× 7 0.1× 25 0.9× 30 1.1× 22 309
Jérémie Larouche Canada 9 24 0.4× 216 4.3× 30 0.6× 93 3.3× 5 0.2× 33 296

Countries citing papers authored by Gulrayz Ahmed

Since Specialization
Citations

This map shows the geographic impact of Gulrayz Ahmed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gulrayz Ahmed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gulrayz Ahmed more than expected).

Fields of papers citing papers by Gulrayz Ahmed

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gulrayz Ahmed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gulrayz Ahmed. The network helps show where Gulrayz Ahmed may publish in the future.

Co-authorship network of co-authors of Gulrayz Ahmed

This figure shows the co-authorship network connecting the top 25 collaborators of Gulrayz Ahmed. A scholar is included among the top collaborators of Gulrayz Ahmed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gulrayz Ahmed. Gulrayz Ahmed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ahmed, Gulrayz, et al.. (2025). The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma. Expert Opinion on Biological Therapy. 25(2). 161–173. 1 indexed citations
2.
Ahmed, Waleed A. Sayed, et al.. (2025). Unveiling WHIM syndrome: Mavorixafor’s emerging role in immune restoration and therapy. Clinical & Experimental Immunology. 219(1). 1 indexed citations
3.
Ahmed, Gulrayz, et al.. (2024). Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma. Expert Review of Anticancer Therapy. 24(8). 705–715. 1 indexed citations
4.
Ahmed, Gulrayz, Anikó Szabó, Mazyar Shadman, et al.. (2024). CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Advances. 8(13). 3528–3531. 2 indexed citations
5.
6.
Ahmed, Gulrayz, Walter Longo, Nirav N. Shah, et al.. (2024). Ruxolitinib Resistance or Intolerance in Steroid-Refractory Chronic Graft-Versus-Host Disease - a Real-World Single Center Analysis. Blood. 144(Supplement 1). 7346–7346. 1 indexed citations
7.
Ahmed, Gulrayz, Pippa Simpson, Donald Basel, et al.. (2024). Reduction in ACE2 expression in peripheral blood mononuclear cells during COVID-19 – implications for post COVID-19 conditions. BMC Infectious Diseases. 24(1). 663–663. 1 indexed citations
8.
Shreenivas, Aditya, James P. Thomas, Susan Tsai, et al.. (2024). Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Therapeutic Advances in Medical Oncology. 16. 12697849–12697849. 2 indexed citations
9.
Thapa, Bicky, Anikó Szabó, Gulrayz Ahmed, et al.. (2023). ATM or CHEK2 alterations: Potential biomarkers of improved outcomes with irinotecan-containing chemotherapy in advanced pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 41(4_suppl). 754–754. 1 indexed citations
10.
Thapa, Bicky, Gulrayz Ahmed, Anikó Szabó, et al.. (2023). Comprehensive genomic profiling: Does timing matter?. Frontiers in Oncology. 13. 1025367–1025367. 4 indexed citations
11.
Ahmed, Gulrayz, Bhavna Bhasin, Anikó Szabó, et al.. (2022). Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. Clinical Lymphoma Myeloma & Leukemia. 22(11). 863–868. 9 indexed citations
12.
Shreenivas, Aditya, Sakti Chakrabarti, James P. Thomas, et al.. (2022). MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in KRAS-mutated advanced pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 40(16_suppl). e16260–e16260. 3 indexed citations
13.
Ahmed, Gulrayz, Mehdi Hamadani, & Nirav N. Shah. (2021). CAR T-cell therapy for secondary CNS DLBCL. Blood Advances. 5(24). 5626–5630. 41 indexed citations
14.
Cain, Michael T., Nathan J. Smith, Pippa Simpson, et al.. (2021). Extracorporeal Membrane Oxygenation with Right Ventricular Assist Device for COVID-19 ARDS. Journal of Surgical Research. 264. 81–89. 44 indexed citations
15.
Brown, Sherry‐Ann, Peter Mason, Jonathan P. Thompson, et al.. (2020). Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology. Frontiers in Cardiovascular Medicine. 7. 568720–568720. 5 indexed citations
16.
17.
Ahmed, Gulrayz & Muhammad Wasif Saif. (2017). Pulmonary Tuberculosis Versus Recurrent Chemotherapy-Induced Pneumonitis: A Clinical Dilemma. Cureus. 9(10). e1742–e1742. 3 indexed citations
18.
Ahmed, Gulrayz, et al.. (2017). Continuing Medical Education: A Cross Sectional Study on a Developing Country’s Perspective. Science and Engineering Ethics. 24(1). 251–260. 8 indexed citations
19.
Ahmed, Gulrayz, et al.. (2013). Weight misperception amongst youth of a developing country: Pakistan -a cross-sectional study. BMC Public Health. 13(1). 707–707. 23 indexed citations
20.
Memon, Zahid, et al.. (2012). Postoperative use of drain in thyroid lobectomy – a randomized clinical trial conducted at Civil Hospital, Karachi, Pakistan. Thyroid Research. 5(1). 9–9. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elliot Dickerson Breakdown of academic impact, for papers by Alexander T. Ruutiainen Breakdown of academic impact, for papers by Varidh Katiyar Breakdown of academic impact, for papers by Lydia Chelala Breakdown of academic impact, for papers by Felicity Allen Breakdown of academic impact, for papers by M. Perrin Breakdown of academic impact, for papers by Paola Solís-Pazmiño Breakdown of academic impact, for papers by Matthew Gardiner Breakdown of academic impact, for papers by Kourosh Karimi Yarandi Breakdown of academic impact, for papers by Jérémie Larouche
Rankless by CCL
2026